EMA Authorised: Nimenrix (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised Nimenrix, a quadrivalent meningococcal conjugate vaccine, for prevention of invasive meningococcal disease caused by serogroups A, C, W-135 a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease

Drugs mentioned

• Nimenrix (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid)

Snippet

Status: Authorised. Therapeutic area: Meningitis, Meningococcal. MAH: Pfizer Europe MA EEIG. Decision date: 12/02/2025